Press Releases

Unigen announces collaboration with Kaya Limited featuring Lumicyn™ in new Kaya® Ultra Glow Sunserum. Clinically proven ingredient for hyperpigmentation.

Unigen's natural ingredient UP302 approved by China NMPA for skin brightening and spot removal - a rare achievement as only the third approval in 30 years.

Unigen’s Mobilix® earns TruShield™ Certified status for anti-doping compliance - clinically proven joint support backed by Univestin®.

Unigen receives China NMPA approval for 99% Bakuchiol as cosmetic ingredient for skin protection, moisturizing, and antioxidant applications (up to 3% usage level).

Unigen Inc. partners with LEHVOSS Nutrition to launch Univestin® + AmLexin™ joint health supplement in Europe. This clinically proven combination supports joint flexibility, comfort, and cartilage protection within days.

Unigen presented breakthrough Maizinol® sleep study results at SLEEP 2025 and NUTRITION 2025. Triple-blind clinical trial showed significant sleep improvements, including reduced sleep latency, fewer awakenings, and increased REM sleep.

Unigen has published promising results in the Journal of Nutrients from a study evaluating Attenutin™ as a natural supplement to combat oxidative stress, chronic inflammation, and compromised immune response, particularly in elderly individuals facing respiratory challenges.

Unigen, Inc. and Science Based Ingredients announce a new distribution partnership in Canada for Unigen’s clinically proven, botanical sleep support and joint health ingredients.

Unigen, Inc. announced positive results from its second clinical trial on Maizinol® conducted by KGK Science, Inc. Results showed statistically-significant improvements in sleep quality, REM and NREM sleep, and total sleep time.

Unigen, Inc. has received COSMOS Approved status for its proprietary cosmeceutial ingredients: Bakutrol®, Bakutrol® A, Lumicyn™ and Lumicyn™ Pure. Its novel ingredient Uniflavon® has also received the COSMOS Approved status through Unigen’s affiliate sister company, Naturetech.

The second pre-clinical study of Symetrian™ (UP360) for effective immune support has been published in the Journal of Immunology Research. The study evaluated Symetrian™ (UP360) as a natural nutritional supplement for a balanced immune response in an accelerated aging in vivo model.

Unigen’s pre-clinical white paper evaluating its standardized botanical antioxidant composition, Attenutin™, has been published on the efficacy in attenuating acute inflammatory lung injury and sepsis.

NIS Labs, in collaboration with Unigen, conducted a controlled clinical study to measure rapid immune activating effects after consuming a single dose of Symetrian (UP360) compared to placebo, which triggered rapid changes to immune surveillance and alertness, as well as increased antioxidant protection in healthy people.

Unigen, Inc. and Viridis BioPharma Pvt. Ltd. announce a new distribution partnership across India for Unigen Beauty’s clinically proven and patented naturally-derived bioactive ingredients.

Unigen has announced the completion of phase I of its groundbreaking Phyto-AI™ project, laying the framework for the use of machine learning and artificial intelligence to collect, analyze and sort the information contained in the PhytoLogix™ technology platform.

Pre-clinical research on UP360 (Symetrian™), Unigen’s novel immune ingredient, has been recently published in the Journal of Medicinal Foods, showing the composition protected against sepsis and mitigated acute lung injury in murine models.

A randomized, triple-blind, placebo-controlled clinical trial involving supplementation with UP360 (Symetrian™) provides evidence for a robust, healthy immune response in healthy adults following influenza vaccination.

Unigen, Inc. and LEHVOSS Personal Care are proud to announce a new distribution partnership across most of Europe for Unigen Beauty’s clinically proven and patented naturally derived active ingredients.

Unigen announced their new partnership with LEHVOSS Nutrition for European distribution of three of Unigen’s patented, clinically proven ingredients: Univestin®, Attenutin™, and Anivestin®.

Unigen has announced the launch of Unigen Beauty, the company’s cosmeceutical ingredient division comprised of clinically proven, patented, and naturally derived bioactives.

A randomized, triple-blind, placebo-controlled clinical trial involving supplementation with a bioflavonoid ingredient UP446 (Attenutin™) provides evidence for a robust, healthy immune response in healthy adults following influenza vaccination.

Unigen Inc. announced the second published clinical study on its Zea mays-derived, patented, clinically proven natural sleep aid Maizinol™ and plans to unveil its latest Zea mays ingredient, SerenZea™ at SupplySide West 2022.

Unigen Inc., showcased its branded ingredient offerings at the recent Vitafoods Europe 2022 in Geneva. Vitafoods Europe is considered the world’s most attended nutraceutical event, attracting over 25,000 industry experts and 1000 + exhibiting brands from over 135 countries.

Unigen Inc. has announced that Dr. Mesfin Yimam, DVM, MS has been elected for a 3-year term to the International Aloe Science Council (IASC) Board of Directors.

Unigen Inc. will introduce two new botanical ingredients at this year's Natural Products Expo West in Anaheim. The new ingredients in Unigen's botanical suite are Attenutin TM for respiratory health, and Symetrian TM for immune homeostasis.

Unigen will introduce its two newest botanical ingredients for sleep/stress and immune health at this year's SupplySide West Presentation Theater. Featured are Maizinol™, a natural alternative to melatonin, and UP360 for maintaining immune homeostasis.

Dr. Jia has worked for the company 25 years since Unigen's inception in 1996. The promotion to President & CEO is part of Unigen's succession planning and positioning for its future and rapid growth.

Mr. Miles has 30+ years of experience in the natural products industry. He has held top leadership positions with many of the leading companies in the industry including Nature's Way, Pharmanex, Integrative Therapeutics, Univera and Next Pharmaceuticals.